Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

Pérez-García et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69e5b71de3767bdea67f89e0 — DOI: https://doi.org/10.1093/neuonc/noac144

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study· 2012 · 740 citations
2. Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies· 2021 · 103 citations
3. Exclusion of patients with brain metastases from cancer clinical trials· 2020 · 34 citations
4. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer· 2022 · 1,093 citations
5. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer· 2019 · 1,298 citations